Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cytotoxic

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    550 result(s) found for: Cytotoxic. Displaying page 1 of 28.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-004682-40 Sponsor Protocol Number: CBYL719K12301 Start Date*: 2021-06-16
    Sponsor Name:Novartis Pharma AG
    Full Title: EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single a...
    Medical condition: Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) PT (Completed) FI (Trial now transitioned) CZ (Completed) DK (Completed) SK (Completed) FR (Completed) NL (Completed) ES (Ongoing) DE (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000998-23 Sponsor Protocol Number: CL1-64315-003 Start Date*: 2019-09-19
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A Phase I/II, open label, non-randomized study to evaluate safety, tolerability, pharmacokinetics and clinical activity of S64315 in patients with locally advanced or metastatic breast cancer in co...
    Medical condition: Locally advanced or metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072740 Locally advanced breast cancer LLT
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005177-29 Sponsor Protocol Number: EORTC 26052-22053 Start Date*: 2006-11-10
    Sponsor Name:EORTC
    Full Title: Phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma
    Medical condition: Patients with Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) FR (Completed) LV (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2019-001946-17 Sponsor Protocol Number: SGNLVA-005 Start Date*: 2019-11-29
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
    Medical condition: Multiple Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020147-12 Sponsor Protocol Number: B1931008 Start Date*: 2011-02-16
    Sponsor Name:Pfizer Inc
    Full Title: AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN ADMINISTERED IN COMBINATION WITH RITUXIMAB COMPARED TO DEFINED INVESTIGATOR’S CHOICE THERAPY IN SUBJECTS WITH RELAPSED OR REFRACTOR...
    Medical condition: Aggressive Non-Hodgkin Lymphoma (NHL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) ES (Completed) DE (Completed) GB (Completed) HU (Completed) LT (Completed) BG (Completed) BE (Completed) GR (Completed) NL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-000712-34 Sponsor Protocol Number: 13-HMedIdeS-03 Start Date*: 2015-02-18
    Sponsor Name:Hansa Medical AB
    Full Title: A PHASE II STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF INTRAVENOUS ASCENDING DOSES OF IDES IN KIDNEY TRANSPLANTATION
    Medical condition: Removal of anti-HLA antibodies in patients planned to undergo kidney transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001834-34 Sponsor Protocol Number: 4919 Start Date*: 2006-03-14
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: Phase 2 trial of neo-adjuvant Oxaliplatin and 5-fluorouracil in oesophageal cancer
    Medical condition: Operable oesophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020821-41 Sponsor Protocol Number: MDV3100-03 Start Date*: 2011-02-10
    Sponsor Name:Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.
    Full Title: PREVAIL: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer W...
    Medical condition: Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) NL (Completed) ES (Completed) SE (Completed) AT (Completed) FI (Completed) DK (Completed) SK (Completed) IT (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016080-11 Sponsor Protocol Number: DIPGstudyVUmc01 Start Date*: 2011-02-25
    Sponsor Name:VU University Medical Center
    Full Title: A COMPREHENSIVE AND TARGETED THERAPY APPROACH IN PEDIATRIC MALIGNANT PONTINE GLIOMAS
    Medical condition: Pediatric malignant pontine gliomas
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006143 Brain stem glioma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003820-36 Sponsor Protocol Number: BAY1841788/17712 Start Date*: 2014-07-25
    Sponsor Name:Bayer AG
    Full Title: A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (DCM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Medical condition: High-risk, non-metastatic castration-resistant prostate cancer (MedDRA: hormonerefractory prostate cancer)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066489 Progression of prostate cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) HU (Completed) FI (Completed) LV (Completed) CZ (Completed) AT (Completed) GB (Completed) SK (Completed) DE (Completed) PT (Completed) IT (Completed) BE (Completed) BG (Completed) FR (Completed) PL (Completed) RO (Completed) LT (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001247-64 Sponsor Protocol Number: CRAD001C2239 Start Date*: 2006-06-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy
    Medical condition: Advanced pancreatic neuroendocrine tumors (NET).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002801-22 Sponsor Protocol Number: X100 Start Date*: 2006-08-18
    Sponsor Name:The Royal Marsden NHSF Trust
    Full Title: Carboplatin Plus Xeloda Followed By Maintenance Xeloda (CARBOX)
    Medical condition: relapsed ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    6 10026662
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001165-15 Sponsor Protocol Number: SIRAC-1 Start Date*: 2007-06-08
    Sponsor Name:University Hospital of Wuerzburg
    Full Title: Sunitinib in Refractory Adrenocortical-Carcinoma patients progressing after cytotoxic chemotherapy (SIRAC)
    Medical condition: Adrenocortical Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001388 Adrenocortical carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001181-38 Sponsor Protocol Number: AuspiCiOus Start Date*: 2021-07-29
    Sponsor Name:Academic Medical Center
    Full Title: Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study
    Medical condition: Gastroesophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005417-13 Sponsor Protocol Number: 13-HMedIdeS-02 Start Date*: 2014-04-24
    Sponsor Name:Hansa Medical AB [...]
    1. Hansa Medical AB
    2. Hansa Medical AB
    Full Title: A PHASE II STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF INTRAVENOUS IDES AFTER ADMINISTRATION OF ASCENDING DOSES IN CHRONIC KIDNEY DISEASE PATIENTS
    Medical condition: Chronic kidney disease (CKD) stage 5 and on waiting list for renal transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000054-63 Sponsor Protocol Number: HNJ-NKAES-2012 Start Date*: 2012-07-25
    Sponsor Name:FUNDACION INVESTIGACION BIOMEDICA HOSPITAL NINO JESUS
    Full Title: Salvage therapy with chemotherapy and Natural Killer cells in relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma.
    Medical condition: Relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma.
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014440-10 Sponsor Protocol Number: EMR200068-006 Start Date*: 2009-12-03
    Sponsor Name:Merck KGaA
    Full Title: A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination with Cetuximab in Second-Line Cetuximab-Naïve Subjects with Recurrent or Metastatic Squ...
    Medical condition: Recurrent/metastatic squamous cell cancer of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) FR (Completed) SK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001772-38 Sponsor Protocol Number: M14-239 Start Date*: 2019-01-29
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) NL (Completed) BE (Trial now transitioned) IT (Trial now transitioned) BG (Completed) CZ (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-007295-14 Sponsor Protocol Number: 26081-22086 Start Date*: 2010-11-17
    Sponsor Name:European Organization for Research and Treatment of Cancer (EORTC)
    Full Title: Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma.
    Medical condition: Newly Diagnosed Anaplastic Glioma with Chromosomal co-deletions of 1p and 19q
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002224 Anaplastic astrocytoma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027744 Mixed astrocytoma-oligodendroglioma LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026659 Malignant oligodendroglioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002453-38 Sponsor Protocol Number: 15-102-14 Start Date*: 2017-01-17
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been...
    Medical condition: Metastatic breast cancer with stable brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) CZ (Completed) BE (Completed) PT (Completed) FR (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 06:43:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA